Compare NICE Ltd (NICE) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NICE Ltd vs Travere Therapeutics Inc. Common Stock — how do they compare? NICE Ltd trades at $110.41 (market cap $6.90B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: NICE Ltd is the larger of the two by market cap, and Travere Therapeutics Inc. Common Stock is trading nearer its 52-week high, NICE Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold NICE Ltd for 16 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| NICE | TVTX | |
|---|---|---|
Market Cap | $6.90B | $4.88B |
Volume | 665,954 | 1,668,577 |
Sector | Technology | Health |
52-Week High | $136.90 | $67.52 |
52-Week Low | $83.15 | $26.79 |
Typical Hold Time | 16 Days | 0 Days |
Enterprise Value | $6.63B | $5.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NICE stock trades at $114.95, down 0.08% on the day, with a bullish technical signal from moving averages and key support at $113. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $2.70 exceeding the $2.63 estimate. Revenue reached $2.95 billion in 2025, though net income is projected to decline to $425 million in 2026. Analyst consensus is a Buy with a $124.20 price target, and recent news highlights leadership in AI-driven contact center platforms.
The outlook for NICE is positive, driven by AI revenue growth and a low valuation, but investors face risks from margin compression due to heavy AI investments and competitive pressures. The stock's current price offers a potential 8% upside to the consensus target, supported by institutional buying interest and solid cash flow generation.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About NICE Ltd
NICE Ltd. is a global leader in both enterprise software and cloud computing, specializing in customer experience and financial crime prevention solutions. The company's platform utilizes advanced analytics, AI, and automation to help organizations enhance customer interactions, ensure compliance, and combat fraud. NICE serves a diverse client base, including contact centers, financial institutions, and government agencies, by optimizing operations and improving service quality.
Read more on NICE →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
